2023年6月2日

分享这篇文章提供的新闻分享这篇文章承认获得高素质的技术生产等离子体衍生品和记录的海外等离子分馏装置建设和技术转让龙仁市,韩国,6月1日2023 / GC生物制药,从韩国生物制药公司,在6月1日宣布,已成功获得最终批准从印尼卫生部等离子分馏装置的建设和技术转让。早在1月,印尼政府选择的公司成功的首选竞购方等离子分馏装置建设的许可和技术转让业务。一些详细的咨询和微调的讨论后,该公司已获得正式批准通知业务。GC生物制药是全球唯一一家成功完成等离子分馏装置交钥匙项目的海外市场。以来第一次等离子分馏装置出口到泰国,GC生物制药已经在海外工厂建设积累经验和知识通过成功的项目在不同的国家包括中国和加拿大。核电站项目是印尼政府的路线图来实现稳定的等离子体衍生品和自给自足供应来自印尼人民的等离子体。目前,该县100%依赖进口等离子体衍生品。”的浩大工程将会是另一个机会,我们是国际公认的杰出的血浆分离技术和公司半个世纪的遗产”,解释GC生物制药和补充说,具体的合同大小和其他细节将签署正式合同后公布。这个项目有意义,这是由于一致的努力,韩国政府和私营部门之间的合作在生物制药领域,导致成功的从一个外国政府招标。GC生物制药在1970年代开始生产白蛋白和自那时以来,它已经产生了各种等离子体衍生品。 Currently, the company supplies 12 products to 32 nations worldwide from its Ochang plant. Established in 2009, the Ochang plant is Asia's largest plasma fractionation plant. About GC Biopharma GC Biopharma (formerly known as Green Cross Corporation) is a biopharmaceutical company that delivers life-saving and life-sustaining protein therapeutics and vaccines. Headquartered in Yongin, South Korea, GC Biopharma is one of the leading plasma protein and vaccine product manufacturers globally and has been dedicated to quality healthcare solutions for more than half a century. This press release may contain biopharmaceuticals in forward-looking statements, which express the current beliefs and expectations of GC Biopharma's management. Such statements do not represent any guarantee by GC Biopharma or its management of future performance and involve known and unknown risks, uncertainties and other factors. GC Biopharma undertakes no obligation to update or revise any forward-looking statement contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. GC Biopharma Contacts (Media)